Max Oliva, Associate Director of IE’s Social Impact Management
The Novartis Institute for Tropical Diseases (NITD) will initiate research on malaria, which together with HIV/AIDS and TB is one of the top three killer diseases in tropical countries.
“With 250 million people infected worldwide and more than one million deaths each year, malaria is one of the most pressing global health issues. This partnership will greatly increase our ability to fight the disease,” Dr. Daniel Vasella, Chairman and CEO of Novartis.
The Public Private Partnership is made up of the NITD, the Wellcome Trust, Singapore Economic Development Board (EDB) and Medicines for Malaria Venture (MMV).
Just as an example of the importance of this, according to the EIRIS Risk Briefing on access to medicines for the developing world and the pharmaceutical industry, in the last 25 years of R&D spending, only 1% was for tropical diseases. Only 10% of global health research is on diseases that account for 90% of the world’s disease burden.
Read more about Novartis on Corpooate Citizenship
Read through these great references from the World Heath Organization WHO
Learn more about Malaria


No comments yet.

Leave a Comment


We use both our own and third-party cookies to enhance our services and to offer you the content that most suits your preferences by analysing your browsing habits. Your continued use of the site means that you accept these cookies. You may change your settings and obtain more information here. Accept